( DENVER--(BUSINESS WIRE)--Jul 2 2007 - ...)Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections,Health

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa infections which are a leading cause of morbidity and mortality in patients with cystic fibrosis. The research appears ahead of print in an advanced online publication of the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.

In the reported research, Dr. Bucki and his colleagues evaluated the activity of a CSA-13, a member of the family of Ceragenin(TM) compounds being developed by Ceragenix. CSA-13 is a synthetic non-peptide mimic of the naturally occurring antimicrobial peptide found in the lung. The researchers found that CSA-13:

-- Is significantly more effective than positively charged antibacterial peptides (LL-37) against a multidrug resistant strain of Pseudomonas aeuroginosa;

-- Is far less susceptible to inactivation by negatively charged components found in the sputa of cystic fibrosis patients (DNA and F-actin); and that

-- Is potent even in cystic fibrosis sputum thereby suggesting potential for therapeutic use.

"This new compound has the potential to be a significant advance in the treatment of patients with cystic fibrosis and other lung infections," says senior author Robert Bucki, a Senior Investigator at the University of Pennsylvania's Institute for Medicine and Engineering.

Normal healthy lungs are protected against bacterial infection by the presence of naturally
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
7. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
8. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
9. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
10. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
11. Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide